Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer.
Ontology highlight
ABSTRACT: Gain-of-function mutations in the androgen receptor (AR) are found in prostate cancer and are implicated in the failure of hormone therapy. Most studies have emphasized the ligand-binding domain (LBD) where mutations can create promiscuous receptors, but mutations in the NH(2)-terminal transactivation domain have also been found. To assess AR alteration as a mechanism of treatment resistance, a mouse model (h/mAR-TRAMP) was used in which the murine AR coding region is replaced by human sequence and prostate cancer initiated by a transgenic oncogene. Mice received either no treatment, androgen depletion by castration, or treatment with antiandrogens, and 20 AR transcripts were sequenced per end-stage tumor. All tumors expressed several mutant alleles, although most mutations were low freque
SUBMITTER: O'Mahony OA
PROVIDER: S-EPMC2748651 | biostudies-literature | 2008 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA